Andrew Schneider, MD
Hematology & Oncology · Tamarac, FLNPI 1548276140
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $966 and has fallen 92.6% since, to $71 in 2024. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 78 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$289
- Pfizer$256
- Sanofi$92
- Takeda Pharmaceuticals U.S.A., Inc.$81
- Array Biopharma Inc$74
- Incyte Corporation$72
- plus $645 from 18 others
Across 100 payments — averaging $4039.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$145K
- Daiichi Sankyo Inc.$98K
- Regeneron$72K
- Bristol Myers Squibb$47K
- Pfizer$38K
- Boehringer Ingelheim Pharma GmbH & Co.kg$2K
- plus $2K from 2 others
What the payments were for
- Food & beverage$1,46697%
- Education$443%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 14 | $289 |
| Pfizer | 16 | $256 |
| Sanofi | 3 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $81 |
| Array Biopharma Inc | 6 | $74 |
| Incyte Corporation | 3 | $72 |
| AstraZeneca | 3 | $69 |
| EMD Serono, Inc. | 3 | $58 |
| Eisai Inc. | 3 | $54 |
| Bristol Myers Squibb | 3 | $53 |
| Taiho Oncology, Inc. | 2 | $52 |
| Novartis | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $46 |
| Sobi, Inc | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Amgen | 2 | $32 |
| Tolmar, Inc. | 1 | $29 |
| Bayer | 1 | $22 |
| GSK | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Tolmar Pharmaceuticals, Inc. | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Gilead | 1 | $12 |
How this compares
$1,510 in reported general payments places this provider in the 35th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 37 | $607,462 |
| Lenalidomide | 29 | $380,182 |
| VenclextaVenetoclax | 26 | $368,239 |
| XtandiEnzalutamide | 15 | $214,438 |
| JakafiRuxolitinib Phosphate | 11 | $194,958 |
| RemicadeInfliximab | 19 | $176,322 |
| NubeqaDarolutamide | 12 | $166,147 |
| Abiraterone Acetate | 26 | $134,344 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 11 | $130,771 |
| RetacritEpoetin Alfa-Epbx | 109 | $124,273 |
| ProcritEpoetin Alfa | 22 | $63,862 |
| ZarxioFilgrastim-Sndz | 13 | $52,624 |
| EliquisApixaban | 18 | $15,440 |
| Imatinib Mesylate | 17 | $4,207 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 24 | $579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Octagam, Retacrit, Eliquis | $256 | $877,946175 claims |
| Johnson & JohnsonRemicade, Procrit | $289 | $240,18441 claims |
| Incyte CorporationJakafi | $72 | $194,95811 claims |
| BayerNubeqa | $22 | $166,14712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Tamarac
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.